

**RECEIVED**

NOV 26 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Re PATENT APPLICATION OF

FREEMAN et al

Atty. Ref.: 39-232

Serial No.: 09/763,236

Group Art Unit: 1635

Filed: June 11, 2001

Examiner: Schmidt, M.

For: DRUG TARGETING

#10/K.T.  
12/6

ELECTION

\* \* \* \* \*

November 25, 2002

RESPONSE

Hon. Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

This in response to the Examiner's requirement for restriction, set forth in the Office Action dated September 25, 2002, the period for response having been extended up to November 25, 2002, by submission of the required petition and fee herewith.

Applicants elect the subject matter of Group I (claims 24-30, 32 and 37-45), with traverse, for prosecution in this application.

With reference to the Examiner's requirement for election of a single linker and specific R1-R4 groups, Applicants elect -NH as the linker, hydrogen as the R1-R3

FREEMAN et al -- Serial No.: 09/763,236

groups and alkyl as the R4 group. This election is made with traverse.

The Examiner is respectfully requested to reconsider the requirement for restriction.

At the outset, the Examiner is reminded that the present application represents the U.S. national phase of a PCT application. No plurality of invention objection was raised during the International phase and thus no requirement for restriction should be made here.

Furthermore, the Examiner's apparent assertions to the contrary, the invention does not relate simply to different, specific groups of compounds. Rather, the invention relates broadly to the principle to "bio-reductive conjugates" from which a drug is released by a through bond elimination reaction on reduction of a nitro group. The broad principle is illustrated in Schemes 1 and 2 which are present on pages 6 and 7 of the specification. It is this broad principle that is covered by claim 1 and that unites all of the various groups of compounds.

An early and favorable Action on the merits is awaited.

FREEMAN et al -- Serial No.: 09/763,236

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson  
Mary J. Wilson  
Reg. No. 32,955

MJW:tat

1100 North Glebe Road  
8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

1628

12

**Nixon & Vanderhye PC.**

ATTORNEY AT LAW

8TH FLOOR  
1100 NORTH GLEBE ROAD  
ARLINGTON, VIRGINIA 22201-4714

TELEPHONE: (703) 816-4000  
FACSIMILE: (703) 816-4100  
WRITER'S DIRECT DIAL NUMBER:  
**(703) 816-4011**

***FACSIMILE COVER SHEET***  
**PLEASE DELIVER IMMEDIATELY!!!!**

Atty Dkt.: 39-232Date: November 25, 2002To: Examiner Schmidt, M. - Group: 1635Firm: USPTOFacsimile No.: (703) 308-4242From: Mary J. Wilson

Number of Pages (including cover sheet): 6  
(IF YOU DO NOT RECEIVE ALL OF THE PAGES OR ENCOUNTER DIFFICULTIES IN TRANSMISSION,  
PLEASE CONTACT US IMMEDIATELY AT (703-816-4000).

Tabitha A. Trice  
FACSIMILE OPERATOR

ATTACHMENT/S: OFFICIAL RESPONSE

FAX RECEIVED

MESSAGE:

NOV 26 2002

In re PATENT APPLICATION OF:

GROUP 1600

FREEMAN et al

Serial No.: 09/763,236

Filed: June 11, 2001

For: DRUG TARGETING

OFFICE

**CONFIDENTIALITY NOTE**

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to arrange for return of the original documents to us.

687367